Catalyst Wire Dossier Catalyst Wire Dossier

MeRes100 Sirolimus-eluting BioResorbable Vascular Scaffold System

sirolimus-eluting bioresorbable vascular scaffold · Meril Life Sciences Pvt. Ltd.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for MeRes100 Sirolimus-eluting BioResorbable Vascular Scaffold System, covering 2026-04-17 to 2026-04-17. Get the full timeline:

Most recent: Clinical Trial Update: Non-inferiority Clinical Trial to Compare the Safety and Performance of MeRes100 Sirolimus-eluting BioResorbable Vascular Scaffold System Versus Contemporary DES Platforms in Patients With de Novo Coronary Artery Lesions [NA]

See pricing